TrialCancer chemotherapy and pharmacology2021

A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects.

Vladimir Hanes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.